Combinatorial Biosynthesis of Fungal Meroterpenoid Assembly Lines

真菌类萜装配线的组合生物合成

• 批准号: 429963852
• 负责人: Professorin Dr. Lena Barra
• 金额: --
• 依托单位: AG Biologische Chemie
• 依托单位国家: 德国
• 项目类别: Research Fellowships
• 财政年份: 2019
• 资助国家: 德国
• 起止时间: 2018-12-31 至 2020-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/429963852?language=en
• 关键词: Combinatorial; Biosynthesis; Fungal; Meroterpenoid; Assembly

The scientific goal of the research project is the utilization of fungal meroterpenoid biosynthetic machineries to generate novel molecular structures with potentially new or improved biological properties by a combinatorial biosynthetic approach.Meroterpenoids belong to a structurally diverse group of hybrid secondary metabolites with pharmaceutically relevant features. Known members of this group and synthetic derivatives thereof are clinically used as immunosuppressant drugs or have been developed as commercial insecticides. Other known meroterpenoids contain structural motifs, which are promising drug leads and are currently investigated for the treatment of atherosclerosis or neurodegenerative diseases like Morbus Alzheimer. Besides chemical synthetic approaches, the combinatorial biosynthesis method is a unique tool to generate novel or altered molecular structures and makes use of the systematic manipulation of metabolic pathways by recombination of different biosynthetic genes. The genetic basis to apply this method to meroterpenoids has only recently been discovered and the rational and controlled recombination of meroterpenoid pathways to create second-generation molecules is the focus of this research project. Specifically, the potential of key enzymes, the recently discovered family of meroterpenoid cyclases, to catalyze formation of new molecular scaffolds will be exploited. For that purpose, their substrate promiscuity will be investigated in detail and based on the obtained results, artificial biosynthetic pathways will be designed and reconstituted in a heterologous host. By this method an efficient production of the new "unnatural" natural products can be achieved and the biological activity of the obtained compounds will be investigated.The results from this research project can potentially contribute to improve human health by obtaining new drug candidates or drug lead structures. At the same time, the in-depth knowledge about the enzymatic basis of meroterpenoid biosynthesis will contribute to future advances to engineer and evolve their catalytic activities to meet human or ecological purposes.

该研究项目的科学目标是利用真菌类化合物的生物合成机制，通过组合生物合成方法产生具有潜在新的或改进的生物学特性的新的分子结构。类化合物是一类结构多样化的杂化次级代谢物，具有药物相关的特征。这一类的已知成员及其合成衍生物在临床上用作免疫抑制药物或已被开发为商业杀虫剂。其他已知的硫代萜类化合物含有结构基序，是很有希望的药物先导，目前正被研究用于治疗动脉粥样硬化或神经退行性疾病，如Morbus阿尔茨海默氏症。除了化学合成方法外，组合生物合成方法是一种独特的产生新的或改变的分子结构的工具，它利用不同的生物合成基因重组来系统地操纵代谢途径。将这种方法应用于硫代萜类化合物的遗传学基础直到最近才被发现，而硫代萜类化合物的合理和可控的重组途径以产生第二代分子是本研究项目的重点。具体地说，将开发关键酶--最近发现的硫代萜类环化酶家族--催化形成新的分子支架的潜力。为此，将详细研究它们的底物混杂，并根据所获得的结果，设计人工生物合成途径，并在异源宿主中进行重组。通过这种方法，可以高效地生产新的非天然天然产物，并对所获得的化合物的生物活性进行研究。本研究项目的结果可能有助于通过获得新的候选药物或药物先导结构来改善人类健康。同时，对硫代萜类化合物生物合成的酶基础的深入了解将有助于未来工程设计和进化其催化活性以满足人类或生态目的。